Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1135041

registered interest
date	26/06/2019
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Probate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, what information he holds on when probate will be granted in the case of Carol Rosalind Green who died on 24 September 2018; and if he will make an assessment of the effect the time taken to grant probate on the ability of the executors to complete the sale of the deceased person's property.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	269608
answer	answer is ministerial correction date of answer 01/07/2019 answer text <p>We are unable to locate the case without further details. If my Hon. Friend writes to me with details of the case, I will ask my officials to look into the matter.</p> answering member constituency South Swindon answering member printed Robert Buckland question first answered 01/07/2019 16:50:57 answering member 4106 label Biography information for Sir Robert Buckland
tabling member	242 label Biography information for Sir Christopher Chope

1135042

registered interest
date	26/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Muscular Atrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the annual cost to the public purse of (a) the decision by NICE in May 2019 to enable people with spinal muscular atrophy to access new drugs and (b) enabling all people with relevant conditions to access those drugs; and if he will make a statement.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	269609
answer	answer is ministerial correction date of answer 01/07/2019 answer text <p>The National Institute for Health and Care Excellence has advised that the total budget impact for the National Health Service at list prices to make nusinersen available for the total population with spinal muscular atrophy has been projected to be £156 million. The actual budget impact is subject to a managed access agreement and a confidential commercial agreement between NHS England and NHS Improvement and the company.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 01/07/2019 15:49:02 answering member 4455 label Biography information for Seema Kennedy
tabling member	242 label Biography information for Sir Christopher Chope

1135043

registered interest
date	26/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Muscular Atrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of people with spinal muscular atrophy will be eligible for access to NHS drugs for treatment following the 15 May 2019 announcement by NICE; what his policy is on people who have been excluded from that access; and if he will make a statement.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	269610
answer	answer is ministerial correction date of answer 01/07/2019 answer text <p>NHS England, NHS Improvement, the National Institute for Health and Care Excellence (NICE) and Biogen have worked together extensively to reach an arrangement that allows access to nusinersen for most people with spinal muscular atrophy types 1, 2 and 3 along with pre-symptomatic patients.</p><p>NICE has advised that because of the difficulties in being confident about the clinical evidence and the cost-effectiveness of nusinersen, it was necessary to agree access criteria for a period of further data collection to try and better understand how nusinersen affects people with spinal muscular atrophy. Therefore a managed access agreement has been reached, which should not only help answer these questions but also address the financial risk and challenges for implementation in the National Health Service.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 01/07/2019 15:54:43 answering member 4455 label Biography information for Seema Kennedy
tabling member	242 label Biography information for Sir Christopher Chope

1135044

registered interest
date	26/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Muscular Atrophy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reason the announcement by NICE on 15 May 2019 that it would facilitate access by people with spinal muscular atrophy to a new drug for prescription on the NHS was followed several weeks later by an announcement that the drug would be available only to a specific group of those people; and if he will make a statement.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	269611
answer	answer is ministerial correction date of answer 01/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) has advised that on 15 May 2019 it confirmed that it was able to recommend nusinersen for the treatment of spinal muscular atrophy. In the announcement, NICE said the treatment would be made available under the terms of the managed access agreement between NHS England and NHS Improvement and Biogen. However, the full detail of the agreement was not given in the announcement and NICE accepts this was misleading for some of the patient population. NICE provided clarification at the earliest opportunity and has apologised to individuals affected.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 01/07/2019 15:53:48 answering member 4455 label Biography information for Seema Kennedy
tabling member	242 label Biography information for Sir Christopher Chope

1135045

registered interest
date	26/06/2019
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Pension Credit
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, what processes he has in place to enable relatives with lasting power of attorney registered with the Public Guardian to apply for pension credit on behalf of those for whom they are responsible; and if he will make a statement.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	269612
answer	answer is ministerial correction date of answer 01/07/2019 answer text <p>The Department for Work and Pensions has processes in place to ensure that someone with a Power of Attorney can make a claim for Pension Credit on behalf of those for whom they are responsible. The Department’s guidance on this is available <a href="https://www.gov.uk/government/publications/procedures-for-dealing-with-agents-appointees-attorneys-deputies-and-third-parties" target="_blank">online</a>.</p><p> </p><p>In order to confirm that an individual has the authority to act on behalf of the claimant, we ask to see the relevant Power of Attorney document and may need to verify authenticity with the Office of the Public Guardian or Office of the Public Guardian (Scotland). The original document can be taken into one of the Department’s offices or sent to the Department; a copy, authenticated by the claimant or donor, a lawyer or a stockbroker as a ‘true copy’, is equally acceptable.</p><p> </p><p>Subject to confirmation that an individual has the authority to act on behalf of the claimant, the simplest method of making a claim is by telephone, which removes the need for claimants and their representatives to complete lengthy application forms. However, paper forms are also available for those who prefer and can be completed with the assistance of a DWP visiting officer if required.</p> answering member constituency Hexham answering member printed Guy Opperman question first answered 01/07/2019 15:57:50 answering member 4142 label Biography information for Guy Opperman
tabling member	242 label Biography information for Sir Christopher Chope